Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M196Revenue (TTM) $M--Net Margin (%)--Altman Z-Score7.8
Enterprise Value $M132EPS (TTM) $-1.1Operating Margin %--Piotroski F-Score2
P/E(ttm)--Beneish M-Score-4.7Pre-tax Margin (%)--Higher ROA y-yN
Price/Book3.310-y EBITDA Growth Rate %--Quick Ratio8.8Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %73.5Current Ratio8.8Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-57.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-62.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M44.3ROIC % (ttm)-509.0Gross Margin Increase y-yN

Gurus Latest Trades with CCXI

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

CCXI is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


CCXI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Tyree James LDirector 2016-05-23Sell5,544$4.390.68view
Edwards Thomas A.Director 2016-05-17Buy50,000$4.059.14view
Edwards Thomas A.Director 2016-05-16Buy25,000$4.059.14view
Parker Geoffrey M.Director 2016-05-13Buy40,000$4.039.68view
KANAYA SUSAN MSVP, Finance, CFO and Sec. 2016-01-22Sell25,764$4.049.41view
KANAYA SUSAN MSVP, Finance, CFO and Sec. 2016-01-20Sell21,405$4.088.33view
Parker Geoffrey M.Director 2016-01-11Buy20,000$4.63-4.54view
KANAYA SUSAN MSVP, Finance, CFO and Sec. 2016-01-08Sell10,224$5.12-13.67view
KANAYA SUSAN MSVP, Finance, CFO and Sec. 2016-01-06Sell47,607$6.98-36.68view
Parker Geoffrey M.Director 2015-12-11Buy20,000$7.25-39.03view

Quarterly/Annual Reports about CCXI:

News about CCXI:

Articles On GuruFocus.com
Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 

More From Other Websites
ChemoCentryx to Present at the Jefferies 2016 Healthcare Conference May 25 2016
ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis... May 23 2016
CHEMOCENTRYX, INC. Financials May 19 2016
XBI and IHI Rose despite the Biotechnology Sector’s Sluggish Week May 16 2016
CHEMOCENTRYX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale... May 12 2016
ChemoCentryx Announces Data Presentation of Novel CCR6 Inhibitors at the 2016 Society for... May 12 2016
Can The Uptrend Continue for ChemoCentryx (CCXI)? May 11 2016
Edited Transcript of CCXI earnings conference call or presentation 10-May-16 12:30pm GMT May 11 2016
ChemoCentryx (CCXI) Shows Strength: Stock Moves Up 42.4% May 11 2016
ChemoCentryx to Host R&D Day on May 18, 2016 May 11 2016
Here’s What You Should Know about These Five Advancing Stocks May 10 2016
CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 10 2016
ChemoCentryx reports 1Q loss May 10 2016
ChemoCentryx reports 1Q loss May 10 2016
Q1 2016 ChemoCentryx Inc Earnings Release - Before Market Open May 10 2016
ChemoCentryx Reports First Quarter 2016 Financial Results and Provides Corporate Update May 10 2016
Vifor Pharma Licenses Rights to Commercialize ChemoCentryx’s Orally-Administered Complement 5aR... May 10 2016
ChemoCentryx to Hold First Quarter 2016 Financial Results Conference Call on Tuesday, May 10, 2016 May 08 2016
ChemoCentryx to Hold First Quarter 2016 Financial Results Conference Call on Tuesday, May 10, 2016 May 05 2016
ChemoCentryx Receives FDA Orphan Products Development Grant for Orally Administered Complement 5a... Apr 28 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)